ORKA

Oruka Therapeutics, Inc.

NASDAQ: ORKA · HEALTHCARE · BIOTECHNOLOGY

$84.46

-1.20% today

Updated 2026-09-25

Market cap

$6.29B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.04

Dividend yield

—

52W range

$15 – $116

Volume

0.9M

Market cap

$6.29B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.04

Dividend yield

—

52W range

$15 – $116

Volume

0.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

8.0

Quality

3.0

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

16.5

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →261 stocks currently score above 75

Price targets

Analyst target

$155.00

+83.52%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Altman Z 16.52 — safe zone

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 1/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-33.15M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	—	—	—	$0.00	$0.00
Net income	$-9.93M	$-5.34M	$-83.72M	$-105.43M	$-41.21M
EPS	—	—	—	—	$-2.04
Free cash flow	$-18.80M	$-10.91M	$-58.03M	$-88.42M	$-33.15M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ORKA	$6.29B	25	4.3	3.0	5.0	8.0	—	Avoid
LLY	$1.03T	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$648.67B	59	4.7	8.5	3.7	5.5	—	Buy
ABBV	$454.36B	73	6.7	8.5	4.0	5.0	-73.51%	Strong Buy
MRK	$365.34B	36	4.0	4.5	2.0	5.0	-78.20%	Hold
UNH	$333.27B	62	7.3	5.5	5.3	5.5	-14.85%	Buy

Smart narrative

Oruka Therapeutics, Inc. trades at $84.46. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 16.52, it sits in the safe zone.

Frequently asked questions

What is Oruka Therapeutics, Inc.'s stock price?

Oruka Therapeutics, Inc. (ORKA) trades at $84.46.

Is Oruka Therapeutics, Inc. overvalued?

Oruka Therapeutics, Inc. carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Oruka Therapeutics, Inc. (ORKA)?

The 12-month analyst consensus target is $155.00, about 83.5% above the current $84.46. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Oruka Therapeutics, Inc.'s Altman Z-Score is 16.52, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-23.89%

Beta-0.21

50D MA$96.29

200D MA$61.11

Shares out0.07B

Float0.06B

Short ratio—

Avg volume0.9M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ORKA vs LLY →ORKA vs JNJ →ORKA vs ABBV →Stock screener →